Form PTO 1449 US Department of Commerce Patent	P-LJ 4857	SERIAL NO. NO. NO. 100/910,582
and Trademark P	APPLICANT: Ruoslahti and MacKenna	GROUP: 00
	FILING DATE: July 20, 2001	GROUP: 8

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
#	5,622,699	04/22/97	Ruoslahti et al.	424	93.6	09/11/95

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
M	WO 97/10507	03/20/97	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

#	Billups et al., "Expression of E-selectin mRNA during ischemia/reperfusion injury," <u>J. Lab. Clin. Med.</u> 125:626-633 (1995).
	Bowles et al., "Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium," <u>Cardiovascular Research</u> 35:422-430 (1997).
	Giordano et al., "Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart," Nature Medicine 2:534-539 (1996).
	Harada et al., "Vascular endothelial growth factor administration in chronic myocardial ischemia," <u>American Journal of Physiol.</u> 270:H1791-H1802 (1996).
	Herskowitz et al., "Cytokine mRNA Expression in Postischemic/Reperfused Myocardium," Am. J. Pathol. 146:419-428 (1995).

EXAMINER	Latin /	Audi —	DATE CONSIDERED	7/20/03	
<u> /v</u>	Contra 1	/\/\/	<u> </u>		لـــــ

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page Form PTO 1449 ATTY DOCKET NO: SERIAL NO. US Department of Commerce Patent P-LJ 4857 09/910,582 and Trademark APPLICANT: Office Ruoslahti and MacKenna TAN O 4 2002 INFORMATION DISCLOSURE FILING DATE: GROUP: STATEMENT BY APPLICAN' July 20, 2001 1653

 TENT & TRADE MAN
Indolfi and Chiariello, "Gene therapy for cardiovascular disorders," Cardiologia 43:365-373 (1998).
Isner et al., "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF $_{165}$ in patient with ischemic limb," The Lancet 348:370-374 (1996).
Knight and Fox, "The Vicious Circle of Ischemic Left Ventricular Dysfunction," Am. J. Cardiol. 75:10E-15E (1995).
Korthuis et al., "Role of Neutrophil-Endothelial cell Adhesion in Inflammatory Disorders," <u>J. Crit. Care</u> 9(1):47-71 (1994).
Kukielka et al., "Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium," <u>Molec. And Cell Biochem.</u> 147:5-12 (1995).
Lefer and Lefer, "Pharmacology of the Endothelium in Ischemia-Reperfusion and Circulatory Shock," <u>Annu. Rev. Pharmacol. Toxicol.</u> 33:71-90 (1993).
Ma et al., "Coronary Endothelial and Cardiac Protective Effects of a Monoclonal Antibody to Intercellular Adhesion Molecule-1 in Myocardial Ischemia and Reperfusion," <u>Circulation</u> 86:937-946 (1992).
Marche et al., "Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy," <u>International Journal of Cardiology</u> 62:S17-S22 (1997).
Meredith et al., "Role of Endothelium in Ischemic Coronary Syndromes," Am. J. Cardiol. 72:27C-32C (1993).
Pasqualini and Ruoslahti, "Organ targeting in vivo using phage display peptide libraries," Nature 380:364-366 (1996).
Rader, "Gene therapy for atherosclerosis," <u>Int. J. Clin. Lab. Res.</u> 27:35-43 (1997).

			<u> </u>
EXAMINER -	them !	Lud	DATE CONSIDERED $7/30/03$
	-	•	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 3 of 3

Form PTO 1449 US Department of Commerce Patent and Trademark Office

ATTY DOCKET NO: P-LJ 4857 SERIAL NO. 09/910,582

APPLICANT:

Ruoslahti and MacKenna

500/29

INFORMATION DISCLOSURE'STATEMENT BY APPLICANT

FILING DATE: July 20, 2001 GROUP:

 LEW 2 TO ADE
Rajotte et al., "Molecular Heterogeneity of the Vascular Endothelium Revealed by in Vivo Phage Display," <u>J. Clin. Invest.</u> 102:430-437 (1998)
Scalia et al., "Myocardial protection by N, N, N -trimethylsphingosine in ischemia reperfusion injury is mediated by inhibition of P-selectin," <u>J. Leukoc. Biol.</u> 59:317-324 (1996).
Schachter, "Calcium antagonists and atherosclerosis," <u>International</u> <u>Journal of Cardiology</u> 62:S9-S15 (1997).
Schachter, "Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers," <u>International Journal of Cardiology</u> 62:S85-S90 (1997).
Seccombe and Schaff, "Coronary Artery Endothelial Function After Myocardial Ischemia and Reperfusion," <u>Ann. Thorac. Surg.</u> 60:778-788 (1995).
Simari and Nabel, "Genetic Therapy," <u>Semin. Intervent. Cardiol.</u> 1:77-83 (1996).
Trost et al., "Protection Against Myocardial Dysfunction After a Brief Ischemic Period in Transgenic Mice Expressing Inducible Heat Shock Protein 70," <u>J. Clin. Invest.</u> 101:855-862 (1998).
Weyrich et al., "Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium," J. Leukoc. Biol. 57:45-55 (1995).
Youker et al., "Molecular Evidence for Induction of Intracellular Adhesion Molecule-1 in the Viable border Zone Associated with Ischemia-Reperfusion Injury of the Dog Heart," Circulation 89:2736-2746 (1994).

EXAMINER	turn /	Lulh	DATE CONSIDERED	7/30/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.